167 related articles for article (PubMed ID: 30267407)
1. Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma.
Orth MF; Gerke JS; Knösel T; Altendorf-Hofmann A; Musa J; Alba-Rubio R; Stein S; Hölting TLB; Cidre-Aranaz F; Romero-Pérez L; Dallmayer M; Baldauf MC; Marchetto A; Sannino G; Knott MML; Wehweck F; Ohmura S; Li J; Hakozaki M; Kirchner T; Dandekar T; Butt E; Grünewald TGP
Int J Cancer; 2019 Feb; 144(4):859-867. PubMed ID: 30267407
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.
Roland CL; May CD; Watson KL; Al Sannaa GA; Dineen SP; Feig R; Landers S; Ingram DR; Wang WL; Guadagnolo BA; Feig B; Hunt KK; Cormier JN; Lazar AJ; Torres KE
Ann Surg Oncol; 2016 Jul; 23(7):2220-8. PubMed ID: 26847678
[TBL] [Abstract][Full Text] [Related]
3. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
[TBL] [Abstract][Full Text] [Related]
4. Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?
Carneiro A; Francis P; Bendahl PO; Fernebro J; Akerman M; Fletcher C; Rydholm A; Borg A; Nilbert M
Lab Invest; 2009 Jun; 89(6):668-75. PubMed ID: 19290004
[TBL] [Abstract][Full Text] [Related]
5. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies.
Toulmonde M; Lucchesi C; Verbeke S; Crombe A; Adam J; Geneste D; Chaire V; Laroche-Clary A; Perret R; Bertucci F; Bertolo F; Bianchini L; Dadone-Montaudie B; Hembrough T; Sweet S; Kim YJ; Cecchi F; Le Loarer F; Italiano A
EBioMedicine; 2020 Dec; 62():103131. PubMed ID: 33254023
[TBL] [Abstract][Full Text] [Related]
6. Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.
Li B; Li L; Li X; Wang Y; Xie Y; Liu C; Li F
Int J Clin Exp Pathol; 2015; 8(7):8563-7. PubMed ID: 26339434
[TBL] [Abstract][Full Text] [Related]
7. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study.
Lahat G; Zhang P; Zhu QS; Torres K; Ghadimi M; Smith KD; Wang WL; Lazar AJ; Lev D
Histopathology; 2011 Sep; 59(3):556-61. PubMed ID: 22034893
[TBL] [Abstract][Full Text] [Related]
8. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
[TBL] [Abstract][Full Text] [Related]
9. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma.
Mito JK; Riedel RF; Dodd L; Lahat G; Lazar AJ; Dodd RD; Stangenberg L; Eward WC; Hornicek FJ; Yoon SS; Brigman BE; Jacks T; Lev D; Mukherjee S; Kirsch DG
PLoS One; 2009 Nov; 4(11):e8075. PubMed ID: 19956606
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Sugaya J; Nakatani F; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2022 Jan; 35(1):384-391. PubMed ID: 34665443
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker.
Villacis RA; Silveira SM; Barros-Filho MC; Marchi FA; Domingues MA; Scapulatempo-Neto C; Aguiar S; Lopes A; Cunha IW; Rogatto SR
PLoS One; 2014; 9(7):e102281. PubMed ID: 25028927
[TBL] [Abstract][Full Text] [Related]
12. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.
Edris B; Espinosa I; Mühlenberg T; Mikels A; Lee CH; Steigen SE; Zhu S; Montgomery KD; Lazar AJ; Lev D; Fletcher JA; Beck AH; West RB; Nusse R; van de Rijn M
J Pathol; 2012 Jun; 227(2):223-33. PubMed ID: 22294416
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
14. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
[TBL] [Abstract][Full Text] [Related]
15. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth.
Tokumoto H; Setoguchi T; Saitoh Y; Sasaki H; Nagano S; Maeda S; Tanimoto A; Taniguchi N
Mol Carcinog; 2019 Dec; 58(12):2230-2240. PubMed ID: 31478563
[TBL] [Abstract][Full Text] [Related]
16. Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need.
Vanni S; Fausti V; Fonzi E; Liverani C; Miserocchi G; Spadazzi C; Cocchi C; Calabrese C; Gurrieri L; Riva N; Recine F; Casadei R; Pieri F; Guerrieri AN; Serra M; Ibrahim T; Mercatali L; De Vita A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108089
[TBL] [Abstract][Full Text] [Related]
17. Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas.
Wong P; Hui A; Su J; Yue S; Haibe-Kains B; Gokgoz N; Xu W; Bruce J; Williams J; Catton C; Wunder JS; Andrulis IL; Gladdy R; Dickson B; O'Sullivan B; Liu FF
Oncotarget; 2015 Nov; 6(36):39127-39. PubMed ID: 25970788
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
19. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions.
Dineen SP; Roland CL; Feig R; May C; Zhou S; Demicco E; Sannaa GA; Ingram D; Wang WL; Ravi V; Guadagnolo A; Lev D; Pollock RE; Hunt K; Cormier J; Lazar A; Feig B; Torres KE
Ann Surg Oncol; 2015 Nov; 22(12):3913-20. PubMed ID: 25743327
[TBL] [Abstract][Full Text] [Related]
20. Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas.
van IJzendoorn DGP; Szuhai K; Briaire-de Bruijn IH; Kostine M; Kuijjer ML; Bovée JVMG
PLoS Comput Biol; 2019 Feb; 15(2):e1006826. PubMed ID: 30785874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
